Personalis, Inc. (PSNL), a genomics company based in Menlo Park, California, focuses primarily on providing cancer genomics services to support the global biopharmaceutical industry's development of personalized cancer treatments. The team at Personalis integrates multidimensional tumor profiling data and information derived from proprietary databases to understand essential cancer biology. This integration provides insights that allow physicians and researchers to devise comprehensive, personalized treatment plans for cancer patients.
Personalis was established in 2011 by a team of genomics veterans from Stanford University who were passionate about making a significant contribution to the field of precision oncology. The company went public on the Nasdaq under the ticker symbol "PSNL" in June 2019.
The company's accreditation and certification as a CAP-accredited and CLIA-certified laboratory underscore its commitment to maintaining the highest standards of clinical laboratory practices. This accreditation enables Personalis to offer its services to both commercial customers and clinical trials.
The key offering from Personalis is the ACE ImmunoID platform. It is a next-generation sequencing (NGS) based platform that provides comprehensive insights into the tumor, microenvironment, and the body's immune response, enabling clinicians and researchers to tailor treatments more effectively and efficiently. The breadth and depth of data generated by this platform have significant implications for the development of individualized immunotherapies.
Personalis's Immunogenomics ID provides biopharmaceutical companies with comprehensive immunogenomics profiling for biomarker discovery, clinical trials, and translational research. It's also vital for the development of new oncology drugs. Moreover, under its NeXT Platform, Personalis offers services such as advanced analytics, data interpretation, and translational informatics to aid in better understanding of cancer genomics.
Notably, Personalis's customer base includes renowned entities that span biopharmaceutical companies, nonprofits, clinical researchers, and leading academic institutions. The company is also a provider to the U.S. Department of Veterans Affairs' Million Veteran Program, which aims to create one of the world's largest medical databases to study the role of genes in health and disease.
While Personalis faces competition from other genomics companies, its unique focus on oncology, robust technological platform, and commitment to research and development sets it apart. It remains at the forefront of helping to unlock the secrets of the human genome to improve cancer outcomes, a testament to its innovative spirit and mission to revolutionize cancer treatment. In the future, Personalis aims to continue expanding the development and application of its pioneering platforms in pursuit of its goal to redefine cancer care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Richard Chen, President and CMO of Personalis, Inc. (NASDAQ:PSNL), sold 3,998 shares of company common stock on September 18, 2026, at $16.22 per share. This sale was an automatic transaction to cover tax withholding obligations from vested restricted stock units. Following the transaction, Chen retains 169,882 shares of Personalis common stock.
Personalis (PSNL) stock has seen a remarkable 250% increase over the past year, reaching a new 3-year high and receiving a 100% "Buy" technical opinion from Barchart. Despite this impressive momentum and strong revenue growth projections, the cancer genomics company remains unprofitable and is considered highly speculative. Analyst sentiment is mixed, and the article emphasizes the need for Personalis to achieve profitability to sustain its growth.
Personalis, Inc. has secured a new task order worth up to US$18.3 million with the U.S. Department of Veterans Affairs’ Million Veteran Program, bringing their total VA MVP task orders to approximately US$243.3 million. While this reinforces Personalis' role in large-scale genomics, the company still faces significant operating losses and high cash burn, with a pending acquisition by Tempus being a key near-term catalyst. Investors should consider these financial challenges despite the expanded VA work.
Personalis Inc. (PSNL) shares dropped 6% after Craig-Hallum downgraded the stock from buy to hold due to skepticism that a competing bid will exceed Tempus AI’s $16.25 per share offer. Despite recent positive clinical trial data from Moderna, which fueled a stock surge, PSNL trades at a Price-to-Sales ratio of 24.16, significantly higher than its historical median, indicating an extreme overvaluation according to GuruFocus’s GF Value™ metric. The company's GF Score™ reflects moderate overall health, but insider selling suggests caution.
Tempus AI (TEM) experienced a significant 40% surge in its stock price this week, adding $3.7 billion to its market capitalization, which is more than double the value of its proposed acquisition of Personalis (PSNL). This increase was driven by encouraging Phase 3 cancer vaccine data from Moderna and Merck, boosting confidence in Tempus's oncology platform. Despite the positive momentum and strong quarterly revenue growth, valuation concerns and analyst divisions remain, with some anticipating a decline from current levels.
Personalis Inc. (PSNL) stock surged 9.41% after announcing an acquisition deal with Tempus AI for $16.25 per share and reporting a strong Q2 revenue beat of $22.4M against a $16.7M consensus. The market is currently pricing PSNL above the offer price, indicating speculation of a higher bid or the value of Tempus stock in the mix. Despite being fundamentally loss-making, the company shows strong unit economics and a solid cash position, supporting the acquisition from a position of strength.
Personalis Inc. (PSNL) stock surged by 9.41% due to investor optimism following the announcement of its acquisition by Tempus AI for $16.25 per share. The acquisition price, coupled with strong Q2 revenue of $22.4M and significant growth in its NeXT Personal MRD test clinical volume, has led to a new uptrend for the stock. While the company still faces profitability challenges, the market is now trading PSNL above the deal price, anticipating potential adjustments or competing offers.
Personalis Inc. (PSNL) stock jumped 9.41% after agreeing to be acquired by Tempus AI for $16.25 per share, valuing the company near $1.5 billion. The deal follows strong Q2 revenue of $22.4M, significantly exceeding expectations, driven by a surge in NeXT Personal MRD test volumes. Despite ongoing profitability challenges, the acquisition provides strategic support, though some shareholder-rights firms are questioning the deal's valuation.
Personalis Inc. (PSNL) stock surged by 9.41% following news of its acquisition by Tempus AI for $16.25 per share. The company reported strong Q2 revenue of $22.4M, exceeding consensus, and a 199% year-over-year increase in clinical volume for its NeXT Personal MRD test. Despite being unprofitable, its robust balance sheet and the acquisition offer provide a new valuation anchor, though some law firms are challenging the fairness of the offer.